Intec pharma ltd. (NTEC)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Jun'17
OPERATING EXPENSES:
RESEARCH AND DEVELOPMENT EXPENSES

-

-

-

-

-

-

-

-

-

5,621

LESS - PARTICIPATION IN RESEARCH AND DEVELOPMENT EXPENSES

-

-

-

-

-

-

-

-

-

0

RESEARCH AND DEVELOPMENT EXPENSES, net

2,024

1,809

8,448

7,860

8,542

10,313

7,809

8,400

8,880

5,621

GENERAL AND ADMINISTRATIVE EXPENSES

1,715

1,796

2,157

2,144

2,190

2,126

1,696

2,194

1,910

-

IMPAIRMENT OF LONG LIVED ASSETS

-

-

-9,759

-

-

-

-

-

-

-

OPERATING LOSS

-3,739

-6,009

-20,364

-10,004

-10,732

-12,439

-9,505

-10,594

-10,790

-

FINANCIAL INCOME (EXPENSES), net

-70

-9

14

33

110

-107

163

-292

124

-

LOSS BEFORE INCOME TAX

-3,809

-6,018

-20,350

-9,971

-10,622

-12,546

-9,342

-10,886

-10,666

-

INCOME TAX

61

538

28

38

34

57

-164

147

63

-

NET LOSS

-3,870

-6,556

-20,378

-10,009

-10,656

-12,603

-9,178

-11,033

-10,729

-

LOSS PER ORDINARY SHARE - BASIC AND DILUTED (in dollars per share)

-0.08

-0.18

-0.61

-0.30

-0.32

-0.37

-0.28

-0.34

-0.41

-

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER ORDINARY SHARE IN THOUSANDS

46

-33,231

33

33,300

33

-58,070

33

32,086

26,076

-

GENERAL AND ADMINISTRATIVE EXPENSES

-

-

-

-

-

-

-

-

-

1,075

OTHER GAINS (LOSSES), net

-

-

-

-

-

-

-

-

-

75

OPERATING LOSS

-

-

-

-

-

-

-

-

-

-6,621

FINANCIAL INCOME

-

-

-

-

-

-

-

-

-

104

FINANCIAL EXPENSES

-

-

-

-

-

-

-

-

-

4

FINANCIAL INCOME (EXPENSES), net

-

-

-

-

-

-

-

-

-

100

LOSS BEFORE TAXES ON INCOME

-

-

-

-

-

-

-

-

-

-6,521

TAXES ON INCOME

-

-

-

-

-

-

-

-

-

0

LOSS AND COMPREHENSIVE LOSS

-

-

-

-

-

-

-

-

-

-6,521

BASIC AND DILUTED LOSS PER ORDINARY SHARE

-

-

-

-

-

-

-

-

-

-0.47